<DOC>
	<DOCNO>NCT00003650</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase III trial study effectiveness combination chemotherapy treat child non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess event free survival 2 5 year child T cell pre-B cell non-Hodgkin 's lymphoma treat sequential induction regimen , consolidation regimen , reintensification regimen , maintenance regimen . - Assess rate local relapse 2 5 year child receive treatment . - Determine toxicity treatment patient . - Determine overall survival child 5 year receive treatment . OUTLINE : This multicenter study . Patients receive 5 week induction chemotherapy consist prednisone IV twice day day 1-28 , decrease dose day 29-35 ; vincristine IV day 8 , 15 , 22 , 29 ; cyclophosphamide IV 1 hour day 8 ; daunorubicin IV 24 hour day 15 , 22 , 29 ; asparaginase IV IM day 16 , 18 , 20 , 23 , 25 , 27 , 30 , 32 ; methotrexate IV 3 hour day 8 . Patients also receive methotrexate methylprednisolone intrathecally ( IT ) day 1 , 4 , 9 , 15 . Patients response 50 % proceed 4-8 week consolidation therapy . This regimen consist vincristine IV day 15 , cyclophosphamide IV 1 hour follow methotrexate 3 hour day 1 , cytarabine IV day 2-5 8-11 , asparaginase IV IM day 16 23 , methotrexate IV 3 hour day 15 . Patients also receive methotrexate methylprednisolone IT day 2 16 . Patients achieve complete remission 4 week repeat consolidation therapy another course . Patients receive 4 week interphase therapy consist oral mercaptopurine day 1 22 , methotrexate IV 3 hour day 1 15 , methotrexate methylprednisolone IT day 2 16 . Patients pre-B cell lymphoma proceed maintenance therapy . Patients T cell lymphoma proceed reinduction therapy . Reinduction A 4 week course chemotherapy administer month 1 , 3 , 5 consists vincristine IV day 1 ; methotrexate IV 3 hour day 1 , 8 , 15 , 22 ; methotrexate methylprednisolone IT day 2 ; asparaginase IM IV day 2 ; oral mercaptopurine . Reinduction B also 4 week course therapy administer month 2 , 4 , 6 . This consist oral prednisone twice day day 1-5 ; cytarabine subcutaneously twice day day 1-4 ; methotrexate IV day 1 , 8 , 15 , 22 ; oral mercaptopurine . Patients proceed maintenance therapy , consist methotrexate mercaptopurine week . Patients stage I , II , III disease continue maintenance therapy 18 month , patient stage IV disease continue therapy 24 month . Patients stage IV disease neuromeningeal involvement receive triple intrathecal therapy consist methotrexate , cytarabine , methylprednisolone , reinduction A month 1 , 2 , 3 , reinduction B month 4 , 5 , 6 ( T cell lymphoma ) . These patient also receive cerebral irradiation month 4 5 . Patients pre-B cell disease receive cerebral irradiation intensification therapy . Patients less 50 % response induction therapy incomplete remission 4-8 week consolidation therapy , recurrence disease treat `` VANDA '' regimen consist dexamethasone day 1-5 ; cytarabine 3 hour twice day day 1 2 ; mitoxantrone IV 1 hour day 3 4 ; etoposide IV 1 hour day 3-5 ; asparaginase IV 1 hour IM day 7 , 9 , 11 , 13 . Patients also receive triple intrathecal therapy ( methotrexate , cytarabine , methylprednisolone ) day 5 . Patients follow every 2 month 1 year , every 3 month 2 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 200 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically and/or cytologically confirm T cell preB cell nonHodgkin 's lymphoma Lymphoblastic peripheral T cell Stage I , II , III , IV No anaplastic lymphoma , large cell lymphoma , small noncleaved cell lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior malignancy No chronic medical psychological condition No congenital immunodeficiency HIV HTLV negative Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid allow Radiotherapy : Not specify Surgery : No prior organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
</DOC>